PsiThera
PrivateLast Round
Series A
Extension
Nov 10, 2026
Total Funding Raised
$72.5M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
PsiThera operates in Healthcare & Life Sciences and is based in Watertown, Massachusetts. Its latest recorded funding round was a Series A Extension round in November 2026.
PsiThera is a biotechnology company that develops oral small-molecule medicines for immunology and inflammatory diseases using its proprietary QUAISAR computational intelligence platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
PsiThera Comparables
Compare PsiThera with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Fathom Therapeutics | 87% | |
| Charm Therapeutics | 85% | |
| Ventus Therapeutics | 85% |
For institutional investors. Book with your work email.
PsiThera Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Nov 10, 2026 | ||||
| Series A | Dec 10, 2025 |
For institutional investors. Book with your work email.
PsiThera Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Lightstone Ventures | Series A, Series A Extension |
| Eurofarma Ventures | Series A |
| AbbVie Ventures | Series A Extension |
| Samsara BioCapital | Series A, Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 10, 2026
$25M round led by Lightstone Ventures and Samsara BioCapital.
- Dec 17, 2025
Eric Shaff, formerly of Seres Therapeutics, named new CEO.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresNov 10, 2026
PsiThera, Inc. appoints Claire Leurent, Ph.D., MBA, Managing Director at AbbVie Ventures, to its Board of Directors in connection with its $25 million financing in Massachusetts on Nov 10th '26.
- receives_financingNov 10, 2026
PsiThera, Inc. receives $25M financing on Nov. 10th '26 in Massachusetts, with participation from AbbVie Ventures, Lumination Capital, Samsara BioCapital, Lightstone Ventures, and other existing investors; proceeds are expected to support TNFα development candidate nomination, IND-enabling studies, and advancement of its oral TL1A program.
For institutional investors. Book with your work email.
PsiThera Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about PsiThera's valuation, stock price, and market status.
Is PsiThera a public or private company?
PsiThera is a private company.
What is the current stock price of PsiThera?
PsiThera is a private company, so its shares have no public market price. Caplight tracks PsiThera's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is PsiThera worth (valuation)?
Valuation information for PsiThera is not publicly available.
Can I buy PsiThera stock?
PsiThera shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was PsiThera's last funding round?
PsiThera's most recent funding round was Series A Extension on November 10, 2026.
Who are the main investors in PsiThera?
Key investors in PsiThera include Lightstone Ventures, Samsara BioCapital.
Will PsiThera IPO soon?
No public IPO plans have been announced for PsiThera.
How can I track PsiThera secondary market activity?
Caplight tracks bids, offers, and trades in PsiThera's shares on secondary markets.